Pembrolizumab Receives FDA Approval for Stage 3. Melanoma Skin Cancer

On 15 February 2019, the United States Food and Drug Administration (FDA), for patients with positive lymph node involvement and malignant melanoma skin cancer, after complete surgical tumor removal, as adjuvant treatment approved an immunotherapy drug, pembrolizumab (Keytruda).
Approval was based on results in surgically completely resected stage IIIA (> 1 mm lymph node metastasis), IIIB, or IIIC melanoma, involving 1019 patients in EORTC1325 / KEYNOTE-054. Patients with mucosal or ocular (eye) melanoma were excluded. Patients were randomly assigned (1:1 ratio) to two arms; one received pembrolizumab every three weeks at 200 mg and the other received placebo . Treatment was planned for up to 1 year, until recurrence or unacceptable toxicity (adverse effects).
The primary endpoint of the studies was recurrence-free survival (relapse free survival, RFS) .
Among patients receiving pembrolizumab, %26 experienced recurrence, compared with placebo recipients at %43, a highly significant difference. Regardless of tumor PD-L1 positivity , pembrolizumab improved recurrence-free survival compared with placebo. Median recurrence-free survival was 20.4 months with placebo, while median RFS had not been reached with pembrolizumab because more than half had not relapsed. Of patients, % 76 received pembrolizumab for 6 months or longer.
Pembrolizumab was discontinued in % 14 of patients because of adverse effects. The most common adverse effects reported in at least % 10 of patients treated with pembrolizumab were diarrhea, itching, nausea, joint pain, hypothyroidism (insufficient thyroid hormone), cough, rash, asthenia (weakness, lack of strength), flu-like illness, weight loss, and hyperthyroidism (excess thyroid hormone).
For adjuvant melanoma treatment, the recommended pembrolizumab dose is, for a maximum of 1 year until recurrence or unacceptable adverse effects, every 3 weeks as a 30-minute IV infusion at 200 mg.
Sources
fda.gov - 15 February 2019
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.